The Molecular Mechanisms of Cancer Program (MMC) brings together basic and translational investigators dedicated to the study of cancer through research in cell signaling, molecular biology, systems biology, developmental biology, and chemistry/drug discovery. The Program has refined its membership from 46 to 36 to reflect increased cancer focus. Peer-reviewed funding of $14,681,074 (annual DC), with $5,863,767 from the NCI, has remained steady despite fewer members. Program members are highly-productive, with 416 peer-reviewed publications, including 12% that were intraprogrammatic, and 26% interprogrammatic publications during the past funding period. Moreover, 38% of these articles were published in high impact (impact factor >10) journals. Although our members'interests are varied, several common themes have emerged. Overall, the basic research objectives of our scientists can be divided into the following five themes: 1) to elucidate the molecular mechanisms of tissue-specific and cell type-specific gene expression;2) to elucidate the cellular mechanisms underlying cell growth/division and cell survival/death;3) to understand the multi-faceted mechanisms leading to cancer metastases;4) to use large-scale, high-throughput systems biology approaches and genetic evolutionary approaches to understand cancer biology;and 5) to discover novel developmental pathways relevant to cancer cell signaling. MMC members'fundamental scientific discoveries in these areas are further encouraged by Program 1 leadership to fuel hypothesis-driven clinical and translational cancer research and to contribute to the broader UCCCC initiative of personalized cancer treatment. Significantly, our membership has developed numerous collaborations with clinician-scientists both within the MMC Program and interprogramatically, reflecting the cross-disciplinary and translational nature of our research program. The MMC Program provides support and the structure for these collaborations among the Program's basic cancer biologists, while primarily representing the broad cancer relevant basic science strengths of the University of Chicago (UChicago). Through pilot funding, quarterly membership meetings, a seminar series, an annual retreat, and a strong basic science training program in cancer biology, the MMC Program is poised to continue its successful in-depth and basic research focus on cancer biology, while nurturing collaborative science that will enhance the clinical care of patients at risk or with cancer.

Public Health Relevance

The Molecular Mechanisms of Cancer Program (MMC) of the University of Chicago Comprehensive Cancer Center brings together cancer biologists studying basic mechanisms of cancer into a focused program where faculty interact in research seminars, program meetings, and in educational and mentoring activities. The basic research performed by MMC investigators plays a key role in uncovering novel mechanisms of cancer biology, thereby leading to improved therapeutic approaches and better patient outcomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014599-38
Application #
8486598
Study Section
Subcommittee G - Education (NCI)
Project Start
2013-04-01
Project End
2018-03-31
Budget Start
2013-04-23
Budget End
2014-03-31
Support Year
38
Fiscal Year
2013
Total Cost
$23,274
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Lee, Ji-Hye; Park, Beom Seok; Han, Kang R et al. (2018) Insight Into the Interaction Between RNA Polymerase and VPg for Murine Norovirus Replication. Front Microbiol 9:1466
Cheng, Jason X; Chen, Li; Li, Yuan et al. (2018) RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun 9:1163
Johnson, Marianna B; Hoffmann, Joscelyn N; You, Hannah M et al. (2018) Psychosocial Stress Exposure Disrupts Mammary Gland Development. J Mammary Gland Biol Neoplasia 23:59-73
Sweis, Randy F; Zha, Yuanyuan; Pass, Lomax et al. (2018) Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer 6:24
Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334
Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966
Sample, Ashley; Zhao, Baozhong; Wu, Chunli et al. (2018) The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochem Photobiol 94:432-437
Hrusch, C L; Manns, S T; Bryazka, D et al. (2018) ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol 11:61-70

Showing the most recent 10 out of 668 publications